Myopia and its prevalence worldwide is rising. A landmark study in 2015 by the Brien Holden Vision Institute (BHVI) estimated that the prevalence of myopia will increase worldwide, from 34% (2.6 billion) of the global population in 2020, to nearly 50% (5 billion) of the world population by 20501. This ultimately means that 1in 2 people are predicted to have myopia in less than 30 years and also that more and more children are developing myopia.
This is significant because studies show that high myopia may lead to severe vision impairment that can no longer be corrected through standard lenses. It can even increase the risk of ocular complications later in life2
Essilor has more than 30 years of research and development experience in myopia and in January 2022 we launched Essilor® Stellest™ lenses which not only correct myopia but also, and above all, slow down its progression.
Essilor® Stellest™ lenses are designed with Highly Aspherical Lenslet Targets or H.A.L.T.3 technology. This game- changing innovation has been proven to slow down myopia progression by 67% on average4
The lenses can be recommended to children as young as six and up to 16 years old, upon the decision of the optician and the benefit this could offer at adulthood is priceless.
For more information, visit: https://global.essilor.com/uk/products/stellest
References:
- Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006
- IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Invest Ophthalmol Vis Sci, 60 (3), M20-M30
- Highly Aspherical Lenslet Target, aspherical lenslets
- Compared to single vision lenses, when worn by children at least 12 hours per day every day. Bao, J., Huang, Y., Li, X., Yang, A., Zhou, F., Wu, J., Wang, C., Li, Y., Lim, E.W., Spiegel, D.P., Drobe, B., Chen, H., 2022. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 140(5), 472–478. https://doi.org/10.1001/jamaophthalmol.2022.0401
